Evidence map›Paper›PMID 41520230›Full record

ArticleBriefings in bioinformatics2026

ProTCR: a protein language model-driven framework for decoding TCR-antigen recognition toward precision immunotherapies.

Minrui Xu, Manman Lu, Peng Liu, Siwen Zhang, Lanming Chen, Qi Liu, Yong Lin, Lu Xie

Abstract read
In one paragraph

Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Minrui XuShanghai-MOST Key Laboratory of Health and Disease Genomics, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai 200237, China.
Manman LuShanghai-MOST Key Laboratory of Health and Disease Genomics, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai 200237, China.
Peng LiuShanghai-MOST Key Laboratory of Health and Disease Genomics, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai 200237, China.
Siwen ZhangShanghai-MOST Key Laboratory of Health and Disease Genomics, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai 200237, China.
Lanming ChenCollege of Food Science and Technology, Shanghai Ocean University, Shanghai 201306, China.
Qi LiuBioinformatics Department, School of Life Sciences and Technology, Tongji University, Shanghai 200092, China.ORCID 0000-0003-2578-1221
Yong LinSchool of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai 200093, China.
Lu XieShanghai-MOST Key Laboratory of Health and Disease Genomics, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai 200237, China.ORCID 0000-0001-7541-2243

Funding

National Center of Technology Innovation for Biopharmaceuticals in China NCTIB2022HS02007National Natural Science Foundation of China 31870829The 2024 STCSM 'Science and Technology Innovation Action Plan' Computational Biology Program in Shanghai 24JS2840300
6 · The paper itself

Abstract

The ability of T-cell receptors (TCRs) to recognize neoantigens is fundamental to the initiation and maintenance of adaptive immune responses. In TCR-based immunotherapies, elucidating the recognition patterns of TCRs for peptides and accurately identifying therapeutically relevant TCR-peptide pairs remain critical challenges. Here, we present a novel dual-pathway network model, ProTCR, which integrates the protein language model ProtT5 with deep learning methods. By incorporating both global and local feature extraction mechanisms, ProTCR enables efficient representation of amino acid sequences, thereby enhancing the model's generalizability across diverse data distributions and improving its biological interpretability. ProTCR demonstrates robust performance and broad applicability across various datasets, including neoantigens, previously unseen peptides, and MHC class II-restricted epitopes, overcoming the reliance on known peptide-TCR pairs observed in previous studies. It also offers new insights for predicting diverse classes of antigenic peptides. We applied ProTCR to several clinically relevant scenarios, including immunotherapeutic target identification in acute myeloid leukemia, neoantigen-targeted immunotherapy in solid tumours, and antigen-specific T cell recognition against pathogens such as influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Across these complex settings, ProTCR consistently maintained high accuracy and stability, demonstrating strong cross-task adaptability and broad potential for clinical application. This work not only provides a powerful tool for elucidating immune response mechanisms but also offers a solid computational foundation for the design of neoantigen or TCR based precision immunotherapy strategies.

Indexed as

ImmunotherapyReceptors, Antigen, T-CellAmino Acid SequenceDeep LearningHumansImmunoinformaticsPeptidesPeptidesReceptors, Antigen, T-Cellmodel interpretabilityprecision immunotherapyprotein language modelTCR-peptides

Identifiers

PMID41520230
PMCPMC12790622

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.